EUVIMEDEUVIMED entdecken
Crossref

Epi-off riboflavin with vitamin E TPGS (Ribocross®) cross-linking: one-year outcome

Pietro Paolo Saba, Alessandro Feo, Luca Pagano, Paolo Vinciguerra, Riccardo Vinciguerra

International Ophthalmology · 2024

DOI: 10.1007/s10792-024-03354-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Ophthalmology, 2024. Verfasst von Pietro Paolo Saba und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy. Hauptthemen laut MEDLINE: Riboflavin, Keratoconus, Cross-Linking Reagents, Vitamin E. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To assess the short and mid-term outcomes of epithelium-off (epi-off) corneal collagen cross-linking using Riboflavin with Vitamin E TPGS (Epi-off Ribocross® CXL) for progressive keratoconus (KC). DESIGN: Retrospective, single-center non-comparative interventional study. METHODS: Patients with progressive keratoconus who underwent CXL using (Epi-off Ribocross® CXL) from May 2021 to May 2022 who completed at least 12 months of follow-up in Humanitas Clinical and Research Center, Rozzano, Milan, Italy. Corrected distance visual acuity with spectable (CDVA), tomographic parameters (Belin ABCD) and topographic parameters were evaluated at baseline and at last follow up. RESULTS: Twenty eyes of twenty patients fulfilled inclusion criteria. CDVA remained stable at last follow up (0.88 ± 0.19 from 0.83 ± 0.21, p = 0.45) with a significant reduction in cylinder (1.97 ± 1.69 from 2.78 ± 2.19, p = 0.03). Kmax significantly improved from 53.18D ± 6.32 to 50.96 ± 5.3D (p = 0.005). At the last follow up, no case of progression was noted. CONCLUSIONS: Epi-off Ribocross® CXL proved to be a safe treatment for progressive KC, with a stabilization of all cases at the one year follow up. Further studies are needed to confirm long-term stability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RiboflavinKeratoconusCross-Linking ReagentsVitamin EVisual AcuityPhotosensitizing AgentsCollagenHumansRetrospective StudiesMaleFemaleAdultYoung AdultFollow-Up StudiesCorneal TopographyTreatment OutcomeUltraviolet RaysPhotochemotherapyAdolescentCorneal Stroma

Stichwörter der Autor:innen

Cross-linkingEpi-offKeratoconusRibocrossVitamin E TPGS

Substanzen

RiboflavinCross-Linking ReagentsVitamin EPhotosensitizing AgentsCollagentocophersolan

Autor:innen und Institutionen

  • Department of Ophthalmology, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.
  • Department of Ophthalmology, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy. Luca.pagano91@hotmail.it.
  • Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy.
  • Department of Ophthalmology, Humanitas San Pio X Hospital, Milan, Italy.

Zitieren

APA

Saba, P. P., Feo, A., Pagano, L., Vinciguerra, P., & Vinciguerra, R. (2024). Epi-off riboflavin with vitamin E TPGS (Ribocross®) cross-linking: one-year outcome. International Ophthalmology. https://doi.org/10.1007/s10792-024-03354-9

Vancouver

Saba PP, Feo A, Pagano L, Vinciguerra P, Vinciguerra R. Epi-off riboflavin with vitamin E TPGS (Ribocross®) cross-linking: one-year outcome. International Ophthalmology. 2024. doi:10.1007/s10792-024-03354-9

BibTeX
@article{Saba2024,
  author = {Saba, Pietro Paolo and Feo, Alessandro and Pagano, Luca and Vinciguerra, Paolo and Vinciguerra, Riccardo},
  title = {Epi-off riboflavin with vitamin E TPGS (Ribocross®) cross-linking: one-year outcome},
  journal = {International Ophthalmology},
  year = {2024},
  doi = {10.1007/s10792-024-03354-9}
}
Kostenlos starten →